{"product_id":"nbtx-vrio-analysis","title":"Nanobiotix S.A. (NBTX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Nanobiotix S.A. (NBTX)'s competitive edge with this focused VRIO Analysis! We've rigorously tested the firm's core assets against the pillars of Value, Rarity, Inimitability, and Organization, and the distilled summary in \u0026amp;O4\u0026amp; reveals the true source of their staying power - or where they might be vulnerable. Don't just guess at their success; read on to see the definitive breakdown of what makes Nanobiotix S.A. (NBTX) tick in today's market.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNanobiotix S.A. (NBTX) - VRIO Analysis: 1. NBTXR3 Physics-Based Mechanism of Action (MoA)\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at a therapeutic approach that fundamentally changes how radiation works inside a tumor, which is a big deal in oncology. The core value of Nanobiotix S.A.'s NBTXR3 is its physics-based mechanism: when activated by radiotherapy, these hafnium oxide nanoparticles cause up to \u003cstrong\u003e9 times\u003c\/strong\u003e the energy to deposit directly into the cancer cells compared to radiation alone. This targeted effect aims to maximize tumor cell death without increasing the dose to surrounding healthy tissue.\u003c\/p\u003e\n\n\u003cp\u003eThis physics-first approach is genuinely rare. Most new cancer therapies are small molecules or biologics; a product designed to amplify radiation energy at the nanoscale is distinct. Honestly, few firms possess the deep, specialized expertise in materials science and radiobiology integration needed to pull this off. That difficulty in replication is key to its defensibility.\u003c\/p\u003e\n\n\u003cp\u003eThe organization's strength is shown by moving from proof-of-concept to late-stage trials. For instance, the Act.In.Sarc trial in soft tissue sarcoma validated the MoA, showing a pathological complete response in \u003cstrong\u003e16%\u003c\/strong\u003e (\u003cstrong\u003e14\u003c\/strong\u003e out of \u003cstrong\u003e87\u003c\/strong\u003e patients) receiving NBTXR3 plus radiation, double the \u003cstrong\u003e8%\u003c\/strong\u003e seen with radiation alone. Plus, the Phase 1 esophageal cancer data showed a complete response in \u003cstrong\u003e6\u003c\/strong\u003e of the \u003cstrong\u003e13\u003c\/strong\u003e patients treated. Furthermore, the company secured a significant financial footing, reporting \u003cstrong\u003e€20.4 million\u003c\/strong\u003e in cash as of September 30, 2025, bolstered by an upfront \u003cstrong\u003e$50 million\u003c\/strong\u003e payment from a royalty financing deal, extending visibility into early 2028. They also completed the sponsorship transfer of the Phase 3 head and neck cancer study (NANORAY-312) to Johnson \u0026amp; Johnson in most regions.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on how we score this resource:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eKey Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e9x\u003c\/strong\u003e energy deposition in tumor cells.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003ePhysics-based MoA is distinct from standard small molecule\/biologic drugs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eRequires specialized materials science and radiobiology integration expertise.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eStrong\u003c\/td\u003e\n\u003ctd\u003eAchieved \u003cstrong\u003e16%\u003c\/strong\u003e pathological complete response in sarcoma trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eThe combination of unique MoA and demonstrated clinical success supports this.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides is that the sustained advantage depends entirely on the Phase 3 NANORAY-312 results and successful commercial scaling with partners. If onboarding takes 14+ days, churn risk rises, but here, the risk is regulatory success.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNanobiotix S.A. (NBTX) - VRIO Analysis: 2. Global Co-Development and Sponsorship Agreement with Johnson \u0026amp; Johnson\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDe-risks the pivotal NANORAY-312 trial by having J\u0026amp;J assume \u003cstrong\u003enearly all\u003c\/strong\u003e remaining costs, significantly extending the cash runway to \u003cstrong\u003emid-2026\u003c\/strong\u003e. Cash position as of March 31, 2025, was \u003cstrong\u003e€39.8 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReduction in operational cash burn due to transfer of NANORAY-312 costs.\u003c\/li\u003e\n\u003cli\u003eOriginal deal value: Approximately \u003cstrong\u003e$2.7 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAmended deal value: Approximately \u003cstrong\u003e$2.6 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eReduction in potential future milestone payments: \u003cstrong\u003e$105 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRare; securing a major pharma partner for global co-development is a huge validation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVery difficult; requires a proven asset and the right strategic fit with a large partner.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEffective; demonstrated by the \u003cstrong\u003eMarch 2025\u003c\/strong\u003e amendment and transfer of sponsorship in most regions. The transfer of US sponsorship for NANORAY-312 was completed in Q4 2024, with global transfer expected by Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestone Category\u003c\/td\u003e\n\u003ctd\u003ePotential Aggregate Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Programs (H\u0026amp;N Cancer, NSCLC)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.77 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Indications Developed by J\u0026amp;J (Five)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$650 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsian Market Developments\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$165 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Indications Developed by Nanobiotix (Per Indication)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$220 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003eTiered royalties on net sales: From the \u003cstrong\u003elow teens\u003c\/strong\u003e to the \u003cstrong\u003elow 20s\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eInitial near-term cash\/support (pre-amendment): Up to \u003cstrong\u003e$60 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eInitial equity investment (pre-amendment): Up to \u003cstrong\u003e$30 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNanobiotix S.A. (NBTX) - VRIO Analysis: 3. Extensive Intellectual Property Portfolio\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eExclusivity secured across three distinct nanotechnology platforms: NBTXR3, Curadigm, and Oocuity. The lead candidate, NBTXR3, is associated with potential success-based payments of up to $1.8 billion from the Janssen collaboration. The company's market capitalization stood at $1.03 billion as of December 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe portfolio is characterized by extensive coverage, comprising more than 300 issued or pending patents and patent applications across over 20 patent families globally. The company's philosophy is rooted in pushing past known boundaries to expand possibilities for human life.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe intellectual property moat is actively reinforced. In November 2025, four new patent applications were filed specifically to expand the Curadigm Nanoprimer intellectual property portfolio. The proprietary know-how in nanoparticle design and manufacture also creates barriers to entry.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProactive management is evidenced by the recent closing of a non-dilutive royalty financing transaction with HCRx valued up to $71 million, extending the cash runway toward long-term growth. The company is dual-listed on Euronext Paris since 2012 and Nasdaq since December 2020.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe core intellectual property assets supporting the platforms are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePlatform\u003c\/th\u003e\n\u003cth\u003ePrimary Application Focus\u003c\/th\u003e\n\u003cth\u003eKey Metric\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNBTXR3\u003c\/td\u003e\n\u003ctd\u003eOncology (Radioenhancer)\u003c\/td\u003e\n\u003ctd\u003eAchieved European market authorization as Hensify®; potential milestone payments up to $1.8 billion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCuradigm\u003c\/td\u003e\n\u003ctd\u003eBioavailability and Biodistribution\u003c\/td\u003e\n\u003ctd\u003eFour new patent applications filed in November 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOocuity\u003c\/td\u003e\n\u003ctd\u003eDisorders of the Central Nervous System\u003c\/td\u003e\n\u003ctd\u003eProtection expected to last until 2029 for NBTXR3 technology patents, with Oocuity being another core platform.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe scope of the IP portfolio includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe total number of umbrella patents is reported as more than 25 across the three platforms.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company's shares outstanding as of December 31, 2024, was 47,426,851.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe stock price had increased by +631.83% in the last 52 weeks as of December 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company's manufacturing site near Paris is expected to expand production capacity to more than 200,000 doses of NBTXR3 per year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNanobiotix S.A. (NBTX) - VRIO Analysis: 4. Non-Dilutive Financing Structure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProvided up to \u003cstrong\u003e$71 million\u003c\/strong\u003e in capital from HealthCare Royalty (HCRx), with \u003cstrong\u003e$50 million\u003c\/strong\u003e upfront, extending cash visibility into early \u003cstrong\u003e2028\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerately rare; securing large, non-dilutive royalty financing is a specific financial maneuver.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; other biotechs can pursue similar deals, but terms are never identical.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEffective; they executed this disciplined financing step, announced on \u003cstrong\u003eOctober 31, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e\n\u003cp\u003eThe structure of the financing agreement includes specific financial obligations and potential outcomes:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Term\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Funding\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$71 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContingent Second Tranche\u003c\/td\u003e\n\u003ctd\u003eAdditional \u003cstrong\u003e$21 million\u003c\/strong\u003e (one year post-closing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepayment Cap (by end of 2030)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$124 million\u003c\/strong\u003e (\u003cstrong\u003e1.75x\u003c\/strong\u003e MOIC)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepayment Cap (thereafter)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$178 million\u003c\/strong\u003e (\u003cstrong\u003e2.50x\u003c\/strong\u003e MOIC)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty-Only Tail Period Cap (Annual)\u003c\/td\u003e\n\u003ctd\u003eNot exceeding \u003cstrong\u003e$14.9 million\u003c\/strong\u003e per year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe financing decision was made against the backdrop of the company's Q3 2025 financial standing:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, Cash Equivalents as of September 30, 2025: \u003cstrong\u003e€20.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Revenue: \u003cstrong\u003e$10.14 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Operating Margin: \u003cstrong\u003e-615.41%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Net Margin: \u003cstrong\u003e-721.67%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Altman Z-Score: \u003cstrong\u003e-1.1\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRepayment obligations are managed through the transfer of receivables from the JNJ-1900 (NBTXR3) license agreement to a French law trust, alongside existing obligations with the European Investment Bank (EIB).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNanobiotix S.A. (NBTX) - VRIO Analysis: 5. Curadigm Nanoprimer Platform Breadth\n\u003c\/h2\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Component\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePlatform potential beyond the lead product, showing preclinical promise in boosting immune responses when combined with therapeutic vaccines.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eRare; having a second, distinct platform technology is uncommon for a company at this stage.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult; requires specialized knowledge in bioavailability and biodistribution.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eEmerging; they have launched Chemistry, Manufacturing, and Controls (CMC) activities to support this pipeline.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary (needs clinical validation).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eValue Supporting Data:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePreclinical data presented at the 2025 Partnership Opportunities in Drug Delivery conference (PODD) established in vivo proof-of-concept for cancer treatment and beyond.\u003c\/li\u003e\n\u003cli\u003eKey preclinical findings included a \u003cstrong\u003eboosted acute immune response\u003c\/strong\u003e following vaccination with mRNA lipoplex vaccines.\u003c\/li\u003e\n\u003cli\u003eKey preclinical findings included an \u003cstrong\u003eimproved memory immune response\u003c\/strong\u003e with mRNA lipoplex vaccines, with similar results observed with peptide-based vaccines.\u003c\/li\u003e\n\u003cli\u003eThese findings will serve as the foundation for the Company's \u003cstrong\u003einitial proprietary pipeline\u003c\/strong\u003e of Nanoprimer products.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\/Imitability Supporting Data:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Curadigm Nanoprimer platform is built from \u003cstrong\u003eprecisely engineered lipid-based nanoparticles\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms, including Curadigm.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFour new patent applications\u003c\/strong\u003e were filed to expand the Curadigm Nanoprimer platform intellectual property portfolio.\u003c\/li\u003e\n\u003cli\u003ePast data demonstrated the Nanoprimer could increase the efficacy of RNA-based therapeutics up to 50% by decreasing rapid liver clearance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization Supporting Data:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eChemistry, Manufacturing, and Controls (CMC) activities launched\u003c\/strong\u003e to support both the internal pipeline and external collaborations.\u003c\/li\u003e\n\u003cli\u003eThe Company has numerous material transfer agreements (MTAs) in place with biotechnology and pharmaceutical partners for exploratory evaluations of Nanoprimer combinations.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and short-term investments were €49.7 million as of December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eThe disciplined financial strategy extended the cash runway into mid-2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNanobiotix S.A. (NBTX) - VRIO Analysis: 6. Clinical Data Across Multiple Solid Tumors\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDemonstrates the potential scalability of NBTXR3 across various cancer types, including esophageal, melanoma, and lung cancer. The mechanism of action is designed to increase the energy deposited by radiotherapy within injected tumor cells up to \u003cstrong\u003e9 times\u003c\/strong\u003e compared to radiotherapy alone.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe drug is being evaluated in ongoing clinical trials spanning an array of solid tumors.\u003c\/li\u003e\n\u003cli\u003eThe company and Janssen have five ongoing clinical trials in advanced solid tumors, including studies in non-small cell lung cancer (NSCLC), pancreatic cancer, and recurrent HNSCC.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerately rare; many single-asset companies focus on only one indication.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDifficult; requires successful execution of multiple investigator-sponsored studies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGood; they are leveraging their academic network to generate diverse data.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe program is led by NANORAY-312 - a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers.\u003c\/li\u003e\n\u003cli\u003eA Phase 1 study in pancreatic cancer was conducted by The University of Texas MD Anderson Cancer Center (“MD Anderson”).\u003c\/li\u003e\n\u003cli\u003eThe company granted Janssen a worldwide license for the development and commercialization of NBTXR3 on July 10, 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe following table summarizes recent clinical data points across multiple solid tumor indications being investigated for NBTXR3 (JNJ-1900):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eStudy Phase\/Design\u003c\/th\u003e\n\u003cth\u003ePatient Cohort Size (Evaluable\/N)\u003c\/th\u003e\n\u003cth\u003eKey Efficacy Metric\u003c\/th\u003e\n\u003cth\u003eReported Number\/Rate\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Cutaneous Melanoma (IO Resistant)\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBest Observed Objective Response Rate (ORR) in all lesions\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e47.4%\u003c\/strong\u003e (\u003cstrong\u003e9\/19\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Cutaneous Melanoma (IO Resistant)\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDisease Control Rate (DCR) in injected \u0026amp; irradiated tumors\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e (\u003cstrong\u003e19\/19\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePancreatic Cancer (Locally Advanced\/Borderline Resectable)\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003en=22\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMedian Overall Survival (OS) from diagnosis\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e23 months\u003c\/strong\u003e [95% CI; \u003cstrong\u003e17 months\u003c\/strong\u003e – not reached]\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePancreatic Cancer (Locally Advanced\/Borderline Resectable)\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003en=22\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCA19-9 normalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e59%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEsophageal Adenocarcinoma (Locally Advanced)\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e13\u003c\/strong\u003e (Early cohorts)\u003c\/td\u003e\n\u003ctd\u003eDisease Control Rate (DCR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEsophageal Adenocarcinoma (Locally Advanced)\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e13\u003c\/strong\u003e (Early cohorts)\u003c\/td\u003e\n\u003ctd\u003eObjective Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e69%\u003c\/strong\u003e (including \u003cstrong\u003e6\u003c\/strong\u003e CR, \u003cstrong\u003e3\u003c\/strong\u003e PR)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEsophageal Adenocarcinoma (Post-Treatment Surgery)\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePathological Complete Response (pCR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvanced Cancers (w\/ anti-PD-1)\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e13\u003c\/strong\u003e (evaluable)\u003c\/td\u003e\n\u003ctd\u003eTumor Regression\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e76.9%\u003c\/strong\u003e (\u003cstrong\u003e10\/13\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained (if data remains positive).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNanobiotix S.A. (NBTX) - VRIO Analysis: 7. Strategic Academic Collaboration Network (MD Anderson)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides access to high-quality, multi-tumor clinical data generation through sponsored Phase 1 and Phase 2 studies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderately rare; the depth and history of this collaboration are a key asset. The broad, comprehensive clinical research collaboration was entered into in \u003cstrong\u003e2019\u003c\/strong\u003e. The initial agreement included a \u003cstrong\u003e$12 million\u003c\/strong\u003e investment to MD Anderson from Nanobiotix. MD Anderson is ranked \u003cstrong\u003eNo. 1\u003c\/strong\u003e in the nation for cancer care.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires established trust and scientific rapport built over years.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Effective; this network is central to their strategy of parallel development.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained.\u003c\/p\u003e\n\u003cp\u003eThe collaboration's scope in clinical data generation is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eInitial Scope\/Status\u003c\/td\u003e\n\u003ctd\u003eProduct\/Study Focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Trials Sponsored\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eNine\u003c\/strong\u003e new Phase I\/II clinical trials\u003c\/td\u003e\n\u003ctd\u003eNBTXR3 across tumor types and combinations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal NBTXR3 Trials Expanded To\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIllustrating dedication to identify more effective treatments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Enrollment Target\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e340\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eAcross various disease stages\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Study Mentioned\u003c\/td\u003e\n\u003ctd\u003eSponsorship transfer to J\u0026amp;J completed in majority of regions\u003c\/td\u003e\n\u003ctd\u003eLocally advanced head and neck cancer (NANORAY-312)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific clinical milestones achieved through the MD Anderson-sponsored studies include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFirst data presented from a Phase 1 study in \u003cstrong\u003eesophageal cancer\u003c\/strong\u003e at the 2025 ASTRO Annual Meeting.\u003c\/li\u003e\n\u003cli\u003eEstablishment of the Recommended Phase 2 Dose (RP2D) at \u003cstrong\u003e33%\u003c\/strong\u003e of gross tumor volume (GTV) in Q4 2024 for the Phase 1 study in locally advanced \u003cstrong\u003eNSCLC amenable to re-irradiation\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCompletion of the dose escalation part of a Phase 1 study in \u003cstrong\u003elocally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe collaboration supports the evaluation of JNJ-1900 (NBTXR3) across tumor types, including studies in \u003cstrong\u003eprimary cutaneous melanoma\u003c\/strong\u003e resistant to anti-PD-1.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAs of September 30, 2025, Nanobiotix reported \u003cstrong\u003e€20.4 million\u003c\/strong\u003e in cash and cash equivalents.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNanobiotix S.A. (NBTX) - VRIO Analysis: 8. Pivotal Phase 3 Trial Momentum (NANORAY-312)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eRepresents the most direct path to potential first-line regulatory approval in locally advanced Head and Neck Squamous Cell Cancers (LA-HNSCC). The study evaluates NBTXR3 activated by Investigator's Choice of Radiotherapy $\\pm$ Cetuximab versus Radiotherapy $\\pm$ Cetuximab in patients aged $\\ge\\mathbf{60}$ years with platinum-ineligible LA-HNSCC. The U.S. Food and Drug Administration granted Fast Track designation for this investigation in February 2020.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eNot rare for a late-stage company, but the specific trial status is key. The study is a global, open-label, two-arm, randomized (\u003cstrong\u003e1:1\u003c\/strong\u003e) Phase 3 registrational study.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eNot easily imitable once underway, but the stage itself is not unique. The trial aims to enroll approximately \u003cstrong\u003e500 patients\u003c\/strong\u003e across sites in the United States, Europe, and Asia.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eStrong; last patient recruited is expected in the \u003cstrong\u003efirst half of 2026 (1H2026)\u003c\/strong\u003e. The Primary Completion date is estimated as \u003cstrong\u003e2026-06-30\u003c\/strong\u003e. The global sponsorship transfer for NANORAY-312 to Johnson \u0026amp; Johnson is complete in the majority of regions.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary (until readout).\u003c\/p\u003e\n\u003cp\u003eThe trial structure and associated data points include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eSource\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Enrollment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e500\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eNANORAY-312 global study size\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Endpoint\u003c\/td\u003e\n\u003ctd\u003eProgression-free Survival (PFS)\u003c\/td\u003e\n\u003ctd\u003eNANORAY-312 pivotal study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Secondary Endpoint\u003c\/td\u003e\n\u003ctd\u003eOverall Survival (OS)\u003c\/td\u003e\n\u003ctd\u003eNANORAY-312 pivotal study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterim Readout Expectation\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e30 months\u003c\/strong\u003e after first patient randomized\u003c\/td\u003e\n\u003ctd\u003eNANORAY-312 timeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFutility Analysis Expectation\u003c\/td\u003e\n\u003ctd\u003eAt \u003cstrong\u003e18 months\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNANORAY-312 timeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Phase 1 Data (Study 102) Median PFS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16.9 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEvaluable population (n=44)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Phase 1 Data (Study 102) Median OS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23.1 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEvaluable population (n=44)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestone Payment Triggered\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$20M\u003c\/strong\u003e from Janssen to Nanobiotix\u003c\/td\u003e\n\u003ctd\u003eAchieved operational milestone in NANORAY-312\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial and operational context supporting the trial momentum:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eJ\u0026amp;J will assume nearly all remaining costs for the ongoing pivotal Phase 3 trial through completion.\u003c\/li\u003e\n\u003cli\u003eThe amendment to the License Agreement provides cash visibility to mid-2026.\u003c\/li\u003e\n\u003cli\u003eCash and Cash Equivalents as of June 30, 2025, were \u003cstrong\u003e€28.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRevenue and other income for the six months ended June 30, 2025, increased to \u003cstrong\u003e€26.6 million\u003c\/strong\u003e, compared to \u003cstrong\u003e€9.3 million\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNanobiotix S.A. (NBTX) - VRIO Analysis: 9. Dual-Exchange Listing and US Operational Presence\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue:\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nThe dual listing enhances access to global capital markets.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eListing on Euronext Paris since \u003cstrong\u003e2012\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eListing on the Nasdaq Global Select Market in New York City since \u003cstrong\u003eDecember 2020\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization as of a recent date: \u003cstrong\u003e€859.198m\u003c\/strong\u003e or \u003cstrong\u003e$1.03 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eShares Outstanding: \u003cstrong\u003e48.21M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eRarity:\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nThe established dual listing is a strategic advantage for global reach.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eExchange\u003c\/th\u003e\n\u003cth\u003eListing Date\u003c\/th\u003e\n\u003cth\u003eTicker\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuronext Paris\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2012\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNANO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNasdaqGS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDec 2020\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNBTX\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eImitability:\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nEasy to imitate by listing elsewhere, but the established history is not.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompany Incorporated in \u003cstrong\u003e2003\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCompany has more than \u003cstrong\u003e25\u003c\/strong\u003e patent families associated with its nanotechnology platforms.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization:\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nEffective; maintaining a key subsidiary in Cambridge, Massachusetts, supports US operations.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHeadquartered in \u003cstrong\u003eParis, France\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSubsidiaries in \u003cstrong\u003eCambridge, Massachusetts (United States)\u003c\/strong\u003e amongst other locations.\u003c\/li\u003e\n\u003cli\u003eUS sponsorship of the global Phase 3 NANORAY-312 study was transferred to Janssen.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage:\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\n\u003cstrong\u003eTemporary\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eFinance:\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nLatest reported cash position and runway projections:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€20.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto early \u003cstrong\u003e2028\u003c\/strong\u003e (contingent on HCRx agreement closing)\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025 update\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eEUR68.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 R\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eEUR40.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe 13-week cash view is to be drafted by Friday.\n\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516214173845,"sku":"nbtx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/nbtx-vrio-analysis.png?v=1740197358","url":"https:\/\/dcf-model.com\/products\/nbtx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}